Feasibility of cabazitaxel in octogenarian prostate cancer patients
| Autor: | Paolo Tralongo, Sebastiano Bordonaro, Giuseppe Di Lorenzo, Ugo De Giorgi, Nicolò Borsellino, Gaetano Facchini, Sabrina Rossetti, Giuseppe Fornarini, Vito Longo, Antonino Carmelo Tralongo, Francesca Caspani, Massimiliano Spada, Nicola Calvani, Paolo Carlini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Current Urology, Vol 17, Iss 3, Pp 153-158 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1661-7649 00000000 |
| DOI: | 10.1097/CU9.0000000000000081 |
| Popis: | Abstract. Background. To evaluate the effectiveness and safety of cabazitaxel in castration-resistant prostate cancer patients aged ≥80 years, we performed a retrospective study on a sample of patients from 11 Italian cancer centers. Materials and methods. Fifty-seven patients aged ≥80 years were treated with cabazitaxel after previous failure with docetaxel; 39 completed a comprehensive geriatric assessment questionnaire (34 fit and 5 vulnerable) and 8 patients (14%) had an Eastern Cooperative Oncology Group performance status (PS) ≥2, while most had a PS of 0–1 (86%). Cabazitaxel was administered at a dose of 25 mg/m2 in 30 (52%) patients and 20 mg/m2 or adapted schedules in 27 (48%) patients. These schedules were adopted mainly in patients ≥85 years (75%), with a PS ≥2 (87.5%), and those classified as vulnerable (100%). Results. The duration of treatment was 4.8 months and was comparable in all subgroups; disease control rate was reported in 36 patients (63%); prostate-specific antigen response was recorded in 18 patients (31.5%). Median overall survival was 13.1 months regardless of age ( |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|